GLP1R and obesity disorder: Recently, a GLP-1 analogue (94% similarity with the native hormone) allowing the weekly administration, i.e. subcutaneous (sc) semaglutide, was introduced to the market for the treatment of T2D and obesity following the large research development SUSTAIN and STEP programs (13–15).